TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22876304

Group type: EXPERIMENTAL
Intervention: Family meetings intervention (n = 96)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care (n = 96)
Number of subjects: 192
Study: 20223872

Group type: EXPERIMENTAL
Intervention: Self sampling for high risk HPV testing
Number of subjects: 28073

Group type: COMPARATOR
Intervention: Recall control group (conventional cytology)
Number of subjects: 28073
Study: 18024537

Group type: EXPERIMENTAL
Intervention: Opportunistic spirometry by visiting trained nurses (TN)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Optimised usual care (UC) from general practitioners (GPs)
Number of subjects: 531
Study: 15983674

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional insulin (CI) therapy
Number of subjects: 14
Study: 12521319

Group type: EXPERIMENTAL
Intervention: alpha lipoic acid for 2 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: carboxymethylcellulose for 2 months (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: alpha lipoic acid for 2 months (after control)
Number of subjects: 22
Study: 10434819

Group type: EXPERIMENTAL
Intervention: i.v. piritramide (nurse-controlled)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: i.v. piritramide (patient-controlled)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: subarachnoid bupivacaine (nurse-controlled)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: subarachnoid bupivacaine (patient-controlled)
Number of subjects: 60
Study: 7824103

Group type: EXPERIMENTAL
Intervention: Proband with affected parent/aunt/uncle (N = 21)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Proband with affected sibling only (N = 11)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Proband with no affected family members (N = 105)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Generational comparison of age at onset
Number of subjects: 137
Study: 2571595

Group type: EXPERIMENTAL
Intervention: Norgestimate (0.25 mg) combined with 0.035 mg ethinyl estradiol (NGM 0.25/35)
Number of subjects: 1261

Group type: COMPARATOR
Intervention: Lo/Ovral (0.30 mg norgestrel combined with 0.030 mg ethinyl estradiol)
Number of subjects: 1261
Study: 565368

Group type: EXPERIMENTAL
Intervention: Adequate sexual role variant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inadequate sexual role variant
Number of subjects: 24
Study: 31088392

Group type: EXPERIMENTAL
Intervention: Ciclosporin Pro (gel-based emulsion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandimmun® Optoral (microemulsion)
Number of subjects: 0
Study: 30077678

Group type: EXPERIMENTAL
Intervention: Distal protection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 200
Study: 26987755

Group type: EXPERIMENTAL
Intervention: Tailor-made notched music training (TMNMT) for two hours a day for three months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Visual Analog Scales
Number of subjects: 100
Study: 25038015

Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Decubitus Position (DP)
Number of subjects: 67
Study: 22666385

Group type: EXPERIMENTAL
Intervention: Peer Review (PR) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Peer Review (non-PR) treatment
Number of subjects: 0
Study: 19617318

Group type: EXPERIMENTAL
Intervention: (18)F-flutemetamol
Number of subjects: 16
Study: 17503661

Group type: EXPERIMENTAL
Intervention: Transient combination antiretroviral treatment (CART)
Number of subjects: 79
Study: 15469659

Group type: EXPERIMENTAL
Intervention: Almond supplementation (52 g/d) for 6 months
Number of subjects: 81
Study: 11462182

Group type: EXPERIMENTAL
Intervention: Zinc bacitracin (n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n=6)
Number of subjects: 12
Study: 10091160

Group type: EXPERIMENTAL
Intervention: Glibenclamide administration
Number of subjects: 33

Group type: COMPARATOR
Intervention: Diet and exercise (Control)
Number of subjects: 33
Study: 7818923

Group type: EXPERIMENTAL
Intervention: Presence of antithyroid antibodies (ATA) in gastric cancer patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Presence of antithyroid antibodies (ATA) in healthy controls
Number of subjects: 32

Group type: COMPARATOR
Intervention: Presence of antithyroid antibodies (ATA) in patients with other malignant tumours (OMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Thyroid function in patients with ATA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation between ATA and chronic gastritis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of ATA incidence between GC patients and controls
Number of subjects: 32
Study: 3259104

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 micrograms intravenously before induction
Number of subjects: 50

Group type: COMPARATOR
Intervention: No sedative or analgesic drugs (Control)
Number of subjects: 50
Study: 28437029

Group type: EXPERIMENTAL
Intervention: High-vegetable diet intervention
Number of subjects: 478

Group type: COMPARATOR
Intervention: Control condition (diet counselling intervention)
Number of subjects: 478
Study: 26604214

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost (2.0 ng/kg/min) continuous infusion for 72 hours postoperatively
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional management (control group)
Number of subjects: 27
Study: 24554548

Group type: COMPARATOR
Intervention: Remifentanil/propofol (RP)‐TIVA
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine/propofol (DP)‐TIVA
Number of subjects: 77
Study: 22913908

Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 20 mg (fasted)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 40 mg (fasted)
Number of subjects: 40

Group type: COMPARATOR
Intervention: indomethacin 50 mg (fasted)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 40 mg (fed)
Number of subjects: 40

Group type: COMPARATOR
Intervention: indomethacin 50 mg (fed)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin 40 mg and indomethacin 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: nano‐formulated indomethacin and standard indomethacin
Number of subjects: 40
Study: 20727331

Group type: EXPERIMENTAL
Intervention: Prednisone plus ginsenosides
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisone plus placebo
Number of subjects: 60
Study: 17912939

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 50

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 50
Study: 15788469

Group type: EXPERIMENTAL
Intervention: Darbepoetin‐alpha (DA) administered subcutaneously weekly
Number of subjects: 162

Group type: COMPARATOR
Intervention: Epoetin‐beta (EB) administered subcutaneously weekly
Number of subjects: 162
Study: 12198060

Group type: EXPERIMENTAL
Intervention: True points acupressure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham points acupressure
Number of subjects: 60

Group type: COMPARATOR
Intervention: No acupressure
Number of subjects: 60
Study: 8765425

Group type: EXPERIMENTAL
Intervention: rhIL-3 at 5 or 10 micrograms/kg per day on days 4-13 after chemotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control cycle (no rhIL-3)
Number of subjects: 41
Study: 2109926

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 clot‐lysis megaunits (cIMU) double‐chain rt‐PA over 1.5 hours followed by 20 cIMU over 5 hours (infusion group, n = 12)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4 intravenous bolus injections of 10 cIMU at 20 minute intervals (bolus group, n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Infusion group
Number of subjects: 26
Study: 285480

Group type: EXPERIMENTAL
Intervention: Adrenaline as a vasoconstrictor additive to 2% Xylocitin at a concentration of 1:100,000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline as a vasoconstrictor additive to 2% Xylocitin at a concentration of 1:100,000
Number of subjects: 0
Study: 31013275

Group type: EXPERIMENTAL
Intervention: LEAN program (Lay health supporters, E-platform, Award, and iNtegration) with mobile text messaging for medication reminders and health education
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group receiving community-based free-medicine program
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: LEAN program
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278
Study: 28521249

Group type: EXPERIMENTAL
Intervention: Videogame simulation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no access to the application)
Number of subjects: 132
Study: 28616874

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 60
Study: 23594362

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C at 320 mg/kg body weight
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C at 480 mg/kg body weight
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 14
Study: 21872169

Group type: EXPERIMENTAL
Intervention: ContaSure Needleless System
Number of subjects: 50
Study: 19576298

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 17630550

Group type: EXPERIMENTAL
Intervention: Interferon-based therapy (peginterferon alfa-2a plus ribavirin)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Baseline HCV-RNA levels (<= 400,000 IU/ml vs > 400,000 IU/ml)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: HCV genotype
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: HIV treatment (with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 853
Study: 14698254

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal standard (IS) - diclofenac
Number of subjects: 0
Study: 11264734

Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN) therapy
Number of subjects: 142

Group type: COMPARATOR
Intervention: No treatment (untreated)
Number of subjects: 142
Study: 9874048

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin infusion (23 patients)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (20 patients, no nitroglycerin)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 43
Study: 8612437

Group type: EXPERIMENTAL
Intervention: Calorie plus fat restriction (CAL + FAT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Calorie restriction (CAL)
Number of subjects: 90
Study: 2474100

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1029010

Group type: EXPERIMENTAL
Intervention: Isoniazid, rifampicin, ethambutol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoniazid, streptomycin and p‐aminosalicylic acid
Number of subjects: 80
Study: 30431501

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique (group US)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Palpation-guided technique (group P)
Number of subjects: 74
Study: 28729361

Group type: EXPERIMENTAL
Intervention: Anacetrapib (100 mg/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/d plus placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Placebo plus Anacetrapib (100 mg/d)
Number of subjects: 39
Study: 25502167

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Durable polymer zotarolimus-eluting stent (DP-ZES)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both stents (BP-SES and DP-ZES)
Number of subjects: 44
Study: 23274615

Group type: EXPERIMENTAL
Intervention: Past‐day Adults' Sedentary Time (PAST) questionnaire
Number of subjects: 90

Group type: COMPARATOR
Intervention: activPAL sit/lie time
Number of subjects: 90
Study: 20824770

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 300

Group type: COMPARATOR
Intervention: TAXUS paclitaxel-eluting stent
Number of subjects: 300
Study: 19820590

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000FORTE
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 16626581

Group type: EXPERIMENTAL
Intervention: Group 2 (7.8-11.0 mmol/L)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Group 3 (≥ 11.0 mmol/L)
Number of subjects: 308
Study: 15562784

Group type: EXPERIMENTAL
Intervention: IVF (Group A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ICSI (Group B)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional IVF (Group E)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: IVF and ICSI (Group C)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ICSI after failed IVF (Group D)
Number of subjects: 61
Study: 11949728

Group type: EXPERIMENTAL
Intervention: Ecologic case-referent design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trial design
Number of subjects: 0
Study: 9156371

Group type: EXPERIMENTAL
Intervention: 600-mg zileuton at 7 AM
Number of subjects: 12

Group type: COMPARATOR
Intervention: 600-mg zileuton at 11 PM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600-mg zileuton four times daily for 5 days
Number of subjects: 12
Study: 7663861

Group type: EXPERIMENTAL
Intervention: Needleless electroacupuncture
Number of subjects: 40
Study: 3191758

Group type: EXPERIMENTAL
Intervention: PA-protocol group
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVP-control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: PA-control group
Number of subjects: 0
Study: 31196366

Group type: EXPERIMENTAL
Intervention: Deep learning based Artificial Intelligence (AI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 200
Study: 29191176

Group type: EXPERIMENTAL
Intervention: eCRF (electronic case report forms)
Number of subjects: 27

Group type: COMPARATOR
Intervention: pCRF (paper case report forms)
Number of subjects: 27
Study: 25408998

Group type: EXPERIMENTAL
Intervention: 12-month walking program (target 150 min/wk, moderate intensity)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (nonwalkers)
Number of subjects: 44
Study: 23875741

Group type: EXPERIMENTAL
Intervention: Combined therapy with tiotropium and formoterol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 38
Study: 21750564

Group type: EXPERIMENTAL
Intervention: Sprinkles
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Foodlets
Number of subjects: 362

Group type: COMPARATOR
Intervention: Drops
Number of subjects: 362
Study: 18832385

Group type: EXPERIMENTAL
Intervention: Cypher stent
Number of subjects: 130

Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 130
Study: 16879518

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (n = 152)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine (n = 155)
Number of subjects: 310
Study: 14738659

Group type: EXPERIMENTAL
Intervention: Screening group (group A) with six monthly alpha-fetoprotein (AFP) assays
Number of subjects: 5581

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 5581

Group type: EXPERIMENTAL
Intervention: Screening group (group A)
Number of subjects: 5581
Study: 10983746

Group type: EXPERIMENTAL
Intervention: Directed social support (DS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Natural social support (NS)
Number of subjects: 56
Study: 9062523

Group type: EXPERIMENTAL
Intervention: Sucrose tablet (3 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspartame-polydextrose tablet (3 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unsweetened polydextrose tablet (3 g)
Number of subjects: 12
Study: 8340445

Group type: EXPERIMENTAL
Intervention: dextroamphetamine (d‐AMPH)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: methylphenidate (MPH)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 3320950

Group type: EXPERIMENTAL
Intervention: ARA‐C + RBZ (with or without CPA)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Age < 40 years
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Age >= 40 years
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Induction regimen with or without CPA
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (CNS prophylaxis and reinductions every 6 weeks for 36 months)
Number of subjects: 91
Study: 29940669

Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day for 28 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26655558

Group type: EXPERIMENTAL
Intervention: cisplatin 100 mg/m(2) with conventional radiotherapy (cis100 + RT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: cisplatin 40 mg/m(2) weekly with accelerated radiotherapy (cis40 + ART)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: cis100 + RT
Number of subjects: 65

Group type: COMPARATOR
Intervention: cis40 + ART
Number of subjects: 65
Study: 25807399

Group type: EXPERIMENTAL
Intervention: Controlled Resuscitation (CR)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard Resuscitation (SR)
Number of subjects: 192
Study: 24338186

Group type: EXPERIMENTAL
Intervention: Maixuekang Capsule (MKC) combined with routine medication
Number of subjects: 236

Group type: COMPARATOR
Intervention: Routine medication (Control)
Number of subjects: 236
Study: 21471106

Group type: EXPERIMENTAL
Intervention: MP-376 120 mg every day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MP-376 240 mg every day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MP-376 240 mg twice a day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MP-376 (all doses)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 18266872

Group type: EXPERIMENTAL
Intervention: Initially non‐submerged implants (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Initially submerged implants (group B)
Number of subjects: 84
Study: 17192453

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) curriculum; n=38
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-evidence-based medicine (non-EBM); n=39
Number of subjects: 77
Study: 12653261

Group type: EXPERIMENTAL
Intervention: Vitamin B12 tablets at a dose of 2 mg 3 times a week for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 11012489

Group type: EXPERIMENTAL
Intervention: Closed-loop administration of propofol/alfentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual control of propofol/alfentanil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Closed-loop administration of isoflurane/nitrous oxide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual control of isoflurane/nitrous oxide
Number of subjects: 100
Study: 8826539

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine hydrochloride (0.9 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 14
Study: 1394810

Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Adriamycin or mitomycin C, given once a week for the first 2 weeks, once every other week for 14 weeks, once a month for 8 months, and once every 3 months for 1 year (total of 21 instillations in 2 years)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Adriamycin or mitomycin C
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Patients with tumor progression
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Patients without tumor progression
Number of subjects: 158
Study: 6327513

Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (200 to 50 mmol/day) over 2 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual high sodium diet
Number of subjects: 52
Study: 31446884

Group type: EXPERIMENTAL
Intervention: Baseline plasma zinc ≥106.9 μg/dL
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Baseline plasma zinc <106.9 μg/dL
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Baseline plasma zinc <103.3 μg/dL
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Baseline plasma zinc ≥103.3 μg/dL
Number of subjects: 1198
Study: 28423932

Group type: EXPERIMENTAL
Intervention: 4-stranded cross-stitch cruciate (4-0 polyester and 4-0 braided suture)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4-stranded double Pennington (2-0 knotless barbed suture)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4-stranded Pennington (4-0 double-stranded braided suture)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 6-stranded modified Lim-Tsai (4-0 looped braided suture)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Braided cruciate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 75
Study: 27320538

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 24569538

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei LP-33
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 22234519

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 166

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 166

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 166
Study: 20445015

Group type: EXPERIMENTAL
Intervention: Phenelzine (15 mg, 3 times daily; positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selegiline (5 mg, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/d for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline (2 mg/d for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline (2 mg/d for 30 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline (4 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline (6 mg/d)
Number of subjects: 0